CD123 specific chimeric antigen receptors for cancer immunotherapy
US9944709B2 · kind B2 · utility
19Cited by
0References
19Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Mar 19, 2015 |
| Grant date | Apr 17, 2018 |
| Priority date | — |
| Expiry date | Mar 19, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a CD123 monoclonal antibody, conferring specific immunity against CD123 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas and leukemia.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.